abiraterone,olaparib
astrazeneca,merck
['abira', 'crpc', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'olaparib', 'propel', 'abiraterone']
#propel met its primary endpoint demonstrating a statistically significant rpfs benefit in the itt population of patients with mcrpc treated with abiraterone + olaparib vs abiraterone + placebo. os trend observed with abiraterone + olaparib #gu23 
Medical oncologist. Lung and genitourinary cancer. #lcsm #pcsm #kcsm